Palomino Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	8.12	0.13	0.14
Cash & Short-Term Investments	8.12	0.13	0.14
Cash Growth	5931.21%	-3.49%	-
Prepaid Expenses	0.31	0	-
Total Current Assets	8.43	0.14	0.14
Total Assets	8.43	0.14	0.14
Accounts Payable	0.23	0	0
Accrued Expenses	0.09	-	-
Short-Term Debt	-	0	0
Other Current Liabilities	0.01	-	-
Total Current Liabilities	0.34	0.01	0.01
Other Long-Term Liabilities	-	0.15	0.14
Total Liabilities	0.34	0.16	0.14
Common Stock	0	0	0
Additional Paid-In Capital	11.28	-	-
Retained Earnings	-3.18	-0.02	-0
Comprehensive Income & Other	-	-0	-
Shareholders' Equity	8.1	-0.02	-0
Total Liabilities & Equity	8.43	0.14	0.14
Total Debt	-	0	0
Net Cash (Debt)	8.12	0.13	0.14
Net Cash Growth	6075.20%	-3.57%	-
Net Cash Per Share	1.21	0.09	0.22
Filing Date Shares Outstanding	18.92	18.77	0.61
Total Common Shares Outstanding	18.77	6	0.61
Working Capital	8.1	0.13	0.13
Book Value Per Share	0.43	-0.00	-0.00
Tangible Book Value	8.1	-0.02	-0
Tangible Book Value Per Share	0.43	-0.00	-0.00